Hypoxia-Inducible factor-1 in physiological and pathophysiological angiogenesis: Applications and therapies

BioMed Research International

Volumn 2015, Issue , 2015, Pages

  Zimna, Agnieszka ^a   Kurpisz, Maciej ^a  

^a INSTITUTE OF HUMAN GENETICS   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; HYPOXIA INDUCIBLE FACTOR 3ALPHA; HIF1A PROTEIN, HUMAN; PGF PROTEIN, HUMAN; PLACENTA PROTEIN; PLACENTAL GROWTH FACTOR; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ADAPTATION; ANGIOGENESIS; CANCER THERAPY; CELL PROLIFERATION; CELL SURVIVAL; GENE TARGETING; GLUCOSE METABOLISM; HUMAN; HYPOXIA; IRON METABOLISM; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; OXYGEN TENSION; PATHOPHYSIOLOGY; REVIEW; CELL HYPOXIA; GENETICS; TRANSCRIPTION INITIATION;

CELL HYPOXIA; HUMANS; HYPOXIA; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; PLACENTA GROWTH FACTOR; PREGNANCY PROTEINS; TRANSCRIPTIONAL ACTIVATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84934987255     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2015/549412     Document Type: Review

References (134)

1. G. L. Semenza, "Hypoxia-inducible factor 1 and cardiovascular disease, " Annual Review of Physiology, vol. 76, pp. 39-56, 2014.
2. P. Carmeliet, "Mechanisms of angiogenesis and arteriogenesis, " Nature Medicine, vol. 6, no. 4, pp. 389-395, 2000.
3. W. Risau, "Mechanisms of angiogenesis, " Nature, vol. 386, no. 6626, pp. 671-674, 1997.
4. W. Risau and I. Flamme, "Vasculogenesis, " Annual Review of Cell and Developmental Biology, vol. 11, pp. 73-91, 1995.
5. P. Carmeliet, "Angiogenesis in health and disease, " Nature Medicine, vol. 9, no. 6, pp. 653-660, 2003.
6. G. D. Yancopoulos, S. Davis, N. W. Gale, J. S. Rudge, S. J. Wieg and , and J. Holash, "Vascular-specific growth factors and blood vessel formation, " Nature, vol. 407, no. 6801, pp. 242-248, 2000.
7. B. P. Eliceiri, R. Paul, P. L. Schwartzberg, J. D. Hood, J. Leng, and D. A. Cheresh, "Selective requirement for Src kinases during VEGF-induced angiogenesis and vascular permeability, " Molecular Cell, vol. 4, no. 6, pp. 915-924, 1999.
8. G. Thurston, J. S. Rudge, E. Ioffe et al., "Angiopoietin-1 protects the adult vasculature against plasma leakage, " Nature Medicine, vol. 6, no. 4, pp. 460-463, 2000.
9. P. C. Maisonpierre, C. Suri, P. F. Jones et al., "Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis, " Science, vol. 277, no. 5322, pp. 55-60, 1997.
10. A. R. Nelson, B. Fingleton, M. L. Rothenberg, and L. M. Matrisian, "Matrix metalloproteinases: biologic activity and clinical implications, " Journal of Clinical Oncology, vol. 18, no. 5, pp. 1135-1149, 2000.
11. E. M. Conway, D. Collen, and P. Carmeliet, "Molecular mechanisms of blood vessel growth, " Cardiovascular Research, vol. 49, no. 3, pp. 507-521, 2001.
12. B. P. Eliceiri and D. A. Cheresh, "The role of v integrins during angiogenesis: insights into potential mechanisms of action and clinical development, " Journal of Clinical Investigation, vol. 103, no. 9, pp. 1227-1230, 1999.
13. M. Corada, M. Mariotti, G. Thurston et al., "Vascular endothelial-cadherin is an important determinant of microvascular integrity in vivo, " Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 17, pp. 9815-9820, 1999.
14. K. A. Knudsen, C. Frankowski, K. R. Johnson, and M. J. Wheelock, "A role for cadherins in cellular signaling and differentiation, " Journal of Cellular Biochemistry, vol. 30-31, pp. 168-176, 1998.
15. P. Lindahl, M. Hellstrom, M. Kalen, and C. Betsholtz, "Endothelial-perivascular cell signaling in vascular development: lessons from knockoutmice, " Current Opinion in Lipidology, vol. 9, no. 5, pp. 407-411, 1998.
16. P. J. Polverini, "The pathophysiology of angiogenesis, " Critical Reviews in Oral Biology and Medicine, vol. 6, no. 3, pp. 230-247, 1995.
17. A. S. Chung, J. Lee, and N. Ferrara, "Targeting the tumour vasculature: insights from physiological angiogenesis, " Nature Reviews Cancer, vol. 10, no. 7, pp. 505-514, 2010.
18. R. S. Kerbel, "Tumor angiogenesis, "The New Engl and Journal of Medicine, vol. 358, no. 19, pp. 2039-2049, 2008.
19. N. Ferrara and R. S. Kerbel, "Angiogenesis as a therapeutic target, " Nature, vol. 438, no. 7070, pp. 967-974, 2005.
20. R. K. Jain, "Molecular regulation of vessel maturation, " Nature Medicine, vol. 9, no. 6, pp. 685-693, 2003.
21. J. A. Nagy, S.-H. Chang, A. M. Dvorak, and H. F. Dvorak, "Why are tumour blood vessels abnormal and why is it important to know?" British Journal of Cancer, vol. 100, no. 6, pp. 865-869, 2009.
22. G. L. Semenza, "Life with oxygen, " Science, vol. 318, no. 5847, pp. 62-64, 2007.
23. J. A. Bertout, S. A. Patel, and M. C. Simon, "The impact of O2 availability on human cancer, " Nature Reviews Cancer, vol. 8, no. 12, pp. 967-975, 2008.
24. B. L. Krock, N. Skuli, and M. C. Simon, "Hypoxia-induced angiogenesis: good and evil, " Genes and Cancer, vol. 2, no. 12, pp. 1117-1133, 2011.
25. Z. Yun, Q. Lin, and A. J. Giaccia, "Adaptive myogenesis under hypoxia, " Molecular and Cellular Biology, vol. 25, no. 8, pp. 3040-3055, 2005.
26. J. I. Bárdos and M. Ashcroft, "Negative and positive regulation of HIF-1: a complex network, " Biochimica et Biophysica Acta-Reviews on Cancer, vol. 1755, no. 2, pp. 107-120, 2005.
27. G. L. Semenza and G. L. Wang, "A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation, " Molecular and Cellular Biology, vol. 12, no. 12, pp. 5447-5454, 1992.
28. G. L. Wang and G. L. Semenza, "Characterization of hypoxiainducible factor 1 and regulation of DNA binding activity by hypoxia, "The Journal of Biological Chemistry, vol. 268, no. 29, pp. 21513-21518, 1993.
29. R. J. Kewley, M. L. Whitelaw, and A. Chapman-Smith, "The mammalian basic helix-loop-helix/PAS family of transcriptional regulators, " International Journal of Biochemistry and Cell Biology, vol. 36, no. 2, pp. 189-204, 2004.
30. G. L. Wang, B.-H. Jiang, E. A. Rue, and G. L. Semenza, "Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellularO2 tension, " Proceedings of the NationalAcademy of Sciences of theUnited States ofAmerica, vol. 92, no. 12, pp. 5510-5514, 1995.
31. S. T. Crews, "Control of cell lineage-specific development and transcription by bHLH-PAS proteins, " Genes and Development, vol. 12, no. 5, pp. 607-620, 1998.
32. R. H. Wenger, D. P. Stiehl, and G. Camenisch, "Integration of oxygen signaling at the consensus HRE, " Sciences STKE, vol. 2005, no. 306, article re12, 2005.
33. J. L. Ruas, L. Poellinger, and T. Pereira, "Functional analysis of hypoxia-inducible factor-1 alpha mediated transactivation. Identification of amino acid residues critical for transcriptional activation and /or interaction with CREB-binding protein, " The Journal of Biological Chemistry, vol. 277, no.41, pp. 38723-38730, 2002.
34. B.-H. Jiang, J. Z. Zheng, S.W. Leung, R. Roe, and G.L. Semenza, "Transactivation and inhibitory domains of hypoxia-inducible factor 1: modulation of transcriptional activity by oxygen tension, " The Journal of Biological Chemistry, vol. 272, no. 31, pp. 19253-19260, 1997.
35. C. W. Pugh, J. F. ORourke, M. Nagao, J. M. Gleadle, and P. J. Ratcliffe, "Activation of hypoxia-inducible factor-1: definition of regulatory domains within the subunit, " The Journal of Biological Chemistry, vol. 272, no. 17, pp. 11205-11214, 1997.
36. B.-H. Jiang, G. L. Semenza, C. Bauer, and H. H. Marti, "Hypoxia-inducible factor 1 levels vary exponentially over a physiologically relevant range of O2 tension, " The American Journal of Physiology-CellPhysiology, vol. 271, no. 4, pp. C1172-C1180, 1996.
37. S. Salceda and J. Caro, "Hypoxia-inducible factor 1 (HIF-1) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions. Its stabilization by hypoxia depends on redox-induced changes, " Journal of Biological Chemistry, vol. 272, no. 36, pp. 22642-22647, 1997.
38. M. Ema, S. Taya, N. Yokotani, K. Sogawa, Y. Matsuda, and Y. Fujii-Kuriyama, "A novel bHLH-PAS factor with close sequence similarity to hypoxia-inducible factor 1 regulates the VEGF expression and is potentially involved in lung and vascular development, " Proceedings of the National Academy of Sciences of the United States of America, vol. 94, no. 9, pp. 4273-4278, 1997.
39. Y.-Z. Gu, S. M. Moran, J. B. Hogenesch, L. Wartman, and C. A. Bradfield, "Molecular characterization and chromosomal localization of a third -class hypoxia inducible factor subunit, HIF3, " Gene Expression, vol. 7, no. 3, pp. 205-213, 1998.
40. Y. Makino, R. Cao, K. Svensson et al., "Inhibitory PAS domain protein is a negative regulator of hypoxia-inducible gene expression, " Nature, vol. 414, no. 6863, pp. 550-554, 2001.
41. W. G. Kaelin Jr., "Proline hydroxylation and gene expression, " Annual Review of Biochemistry, vol. 74, pp. 115-128, 2005.
42. V. Srinivas, L.-P. Zhang, X.-H. Zhu, and J. Caro, "Characterization of an oxygen/redox-dependent degradation domain of hypoxia-inducible factor (HIF-) proteins, " Biochemical and Biophysical Research Communications, vol. 260, no. 2, pp. 557-561, 1999.
43. N. Masson and P. J. Ratcliffe, "HIF prolyl and asparaginyl hydroxylases in the biological response to intracellular O2 levels, " Journal of Cell Science, vol. 116, no. 15, pp. 3041-3049, 2003.
44. N. Masson, C. Willam, P. H. Maxwell, C. W. Pugh, and P. J. Ratcliffe, "Independent function of two destruction domains in hypoxia-inducible factor-chains activated by prolyl hydroxylation, " EMBO Journal, vol. 20, no. 18, pp. 5197-5206, 2001.
45. L. A. McNeill, K. S. Hewitson, J. M. Gleadle et al., "The use of dioxygen by HIF prolyl hydroxylase (PHD1), " Bioorganic & Medicinal Chemistry Letters, vol. 12, no. 12, pp. 1547-1550, 2002.
46. K. S. Hewitson, L. A. McNeill, M. V. Riordan et al., "Hypoxiainducible factor (HIF) asparagine hydroxylase is identical to factor inhibiting HIF (FIH) and is related to the cupin structural family, " The Journal of Biological Chemistry, vol. 277, no. 29, pp. 26351-26355, 2002.
47. D. L and o, D. J. Peet, D. A. Whelan, J. J. Gorman, and M. L. Whitelaw, "Asparagine hydroxylation of the HIF transactivation domain: a hypoxic switch, " Science, vol. 295, no. 5556, pp. 858-861, 2002.
48. D. L and o, D. J. Peet, J. J. Gorman, D. A. Whelan, M. L. Whitelaw, and R. K. Bruick, "FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of hypoxia-inducible factor, " Genes and Development, vol. 16, no. 12, pp. 1466-1471, 2002.
49. P. C. Mahon, K. Hirota, and G. L. Semenza, "FIH-1: a novel protein that interacts with HIF-1 and VHL to mediate repression of HIF-1 transcriptional activity, " Genes and Development, vol. 15, no. 20, pp. 2675-2686, 2001.
50. W. G. Kaelin Jr. and P. J. Ratcliffe, "Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway, " Molecular Cell, vol. 30, no. 4, pp. 393-402, 2008.
51. C. J. Schofield and Z. Zhang, "Structural and mechanistic studies on 2-oxoglutarate-dependent oxygenases and related enzymes, " Current Opinion in Structural Biology, vol. 9, no. 6, pp. 722-731, 1999.
52. Q. Ke and M. Costa, "Hypoxia-inducible factor-1 (HIF-1), " Molecular Pharmacology, vol. 70, no. 5, pp. 1469-1480, 2006.
53. D. J. Manalo, A. Rowan, T. Lavoie et al., "Transcriptional regulation of vascular endothelial cell responses to hypoxia by HIF-1, " Blood, vol. 105, no. 2, pp. 659-669, 2005.
54. P. J. Kallio, I. Pongratz, K. Gradin, J. McGuire, and L. Poellinger, "Activation of hypoxia-inducible factor 1: posttranscriptional regulation and conformational change by recruitment of the Arnt transcription factor, " Proceedings of the National Academy of Sciences of the United States of America, vol. 94, no. 11, pp. 5667-5672, 1997.
55. P. J. Kallio, K. Okamoto, S.OBrien et al., "Signal transduction in hypoxic cells: inducible nuclear translocation and recruitment of the CBP/p300 coactivator by the hypoxia-inducible factor-1, " The EMBO Journal, vol. 17, no. 22, pp. 6573-6586, 1998.
56. G. L. Semenza, M. K. Nejfelt, S. M. Chi, and S. E. Antonarakis, "Hypoxia-inducible nuclear factors bind to an enhancer element located 3 to the human erythropoietin gene, " Proceedings of the National Academy of Sciences of the United States of America, vol. 88, no. 13, pp. 5680-5684, 1991.
57. T. N. Seagroves, H. E. Ryan, H. Lu et al., "Transcription factor HIF-1 is a necessary mediator of the pasteur effect in mammalian cells, " Molecular and Cellular Biology, vol. 21, no. 10, pp. 3436-3444, 2001.
58. C. V. Dang and G. L. Semenza, "Oncogenic alterations of metabolism, " Trends in Biochemical Sciences, vol. 24, no. 2, pp. 68-72, 1999.
59. G. L. Semenza, P. H. Roth, H.-M. Fang, and G. L. Wang, "Transcriptional regulation of genes encoding glycolytic enzymes by hypoxia-inducible factor 1, " The Journal of Biological Chemistry, vol. 269, no. 38, pp. 23757-23763, 1994.
60. R. H. Wenger, "Cellular adaptation to hypoxia: O2-sensing protein hydroxylases, hypoxia-inducible transcription factors, and O2-regulated gene expression, " The FASEB Journal, vol. 16, no. 10, pp. 1151-1162, 2002.
61. G. L. Semenza, "Regulation of metabolism by hypoxiainducible factor 1, " Cold SpringHarbor Symposia onQuantitative Biology, vol. 76, pp. 347-353, 2011.
62. D. Feldser, F. Agani, N. V. Iyer, B. Pak, G. Ferreira, and G. L. Semenza, "Reciprocal positive regulation of hypoxia-inducible factor 1alpha and insulin-like growth factor 2, " Cancer Research, vol. 59, no. 16, pp. 3915-3918, 1999.
63. B. Krishnamachary, S. Berg-Dixon, B. Kelly et al., "Regulation of colon carcinoma cell invasion by hypoxia-inducible factor 1, " Cancer Research, vol. 63, no. 5, pp. 1138-1143, 2003.
64. M. Koning, P. M. N. Werker, M. J. A. van Luyn, and M. C. Harmsen, "Hypoxia promotes proliferation of humanmyogenic satellite cells: a potential benefactor in tissue engineering of skeletalmuscle, " Tissue Engineering A, vol. 17, no. 13-14, pp. 1747-1758, 2011.
65. J. A. Mitchell and J. M. Yochim, "Intrauterine oxygen tension during the estrous cycle in the rat: its relation to uterine respiration and vascular activity, " Endocrinology, vol. 83, no. 4, pp. 701-705, 1968.
66. F. Rodesch, P. Simon, C. Donner, and E. Jauniaux, "Oxygen measurements in endometrial and trophoblastic tissues during early pregnancy, " Obstetrics and Gynecology, vol. 80, no. 2, pp. 283-285, 1992.
67. H. Diez, A. Fischer, A. Winkler et al., "Hypoxia-mediated activation of Dll4-Notch-Hey2 signaling in endothelial progenitor cells and adoption of arterial cell fate, " Experimental Cell Research, vol. 313, no. 1, pp. 1-9, 2007.
68. D. M. Adelman, E. Maltepe, and M. C. Simon, "Multilineage embryonic hematopoiesis requires hypoxic ARNT activity, " Genes and Development, vol. 13, no. 19, pp. 2478-2483, 1999.
69. N. V. Iyer, L. E. Kotch, F. Agani et al., "Cellular and developmental control of O2 homeostasis by hypoxia-inducible factor 1, " Genes & Development, vol. 12, no. 2, pp. 149-162, 1998.
70. K. R. Kozak, B. Abbott, and O. Hankinson, "ARNT-deficient mice and placental differentiation, " Developmental Biology, vol. 191, no. 2, pp. 297-305, 1997.
71. D. M. Adelman, M. Gertsenstein, A. Nagy, M. C. Simon, and E. Maltepe, "Placental cell fates are regulated in vivo by HIFmediated hypoxia responses, " Genes and Development, vol. 14, no. 24, pp. 3191-3203, 2000.
72. K. D. Cowden Dahl, B. H. Fryer, F. A. Mack et al., "Hypoxiainducible factors 1 and 2 regulate trophoblast differentiation, " Molecular and Cellular Biology, vol. 25, no. 23, pp. 10479-10491, 2005.
73. K. Takeda, V. C. Ho, H. Takeda, L. J. Duan, A. Nagy, and G.-H. Fong, "Placental but not heart defects are associated with elevated hypoxia-inducible factor levels in mice lacking prolyl hydroxylase domain protein 2, " Molecular and Cellular Biology, vol. 26, no. 22, pp. 8336-8346, 2006.
74. E. Maltepe, J.V. Schmidt, D. Baunoch, C. A. Bradfield, and M. C. Simon, "Abnormal angiogenesis and responses to glucose and oxygen deprivation in mice lacking the protein ARNT, " Nature, vol. 386, no. 6623, pp. 403-407, 1997.
75. D. L. Ramirez-Bergeron, A. Runge, D. M. Adelman, M. Gohil, and M. C. Simon, "HIF-dependent hematopoietic factors regulate the development of the embryonic vasculature, " Developmental Cell, vol. 11, no. 1, pp. 81-92, 2006.
76. A. E. Greijer, P. van der Groep, D. Kemming et al., "Upregualtion of gene expression by hypoxia is mediated predominantly by hypoxia-inducible factor I (HIF-I), " Journal of Pathology, vol. 206, no. 3, pp. 291-304, 2005.
77. G. L. Semenza, "Angiogenesis in ischemic and neoplastic disorders, " Annual Review of Medicine, vol. 54, pp. 17-28, 2003.
78. D. J. Ceradini, A. R. Kulkarni, M. J. Callaghan et al., "Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1, " Nature Medicine, vol. 10, no. 8, pp.858-864, 2004.
79. J. E. Park, G.-A. Keller, and N. Ferrara, "The vascular endothelial growth factor (VEGF) isoforms: differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF, " Molecular Biology of the Cell, vol. 4, no. 12, pp. 1317-1326, 1993.
80. Y. Liu, S. R. Cox, T. Morita, and S. Kourembanas, "Hypoxia regulates vascular endothelial growth factor gene expression in endothelial cells: Identification of a 5enhancer, " Circulation Research, vol. 77, no. 3, pp. 638-643, 1995.
81. J. A. Forsythe, B.-H. Jiang, N. V. Iyer et al., "Activation of vascular endothelial growth factor gene transcription by hypoxiainducible factor 1, "Molecular and Cellular Biology, vol. 16, no. 9, pp. 4604-4613, 1996.
82. H.-P. Gerber, F. Condorelli, J. Park, and N. Ferrara, "Differential transcriptional regulation of the two vascular endothelial growth factor receptor genes. Flt-1, but not Flk-1/KDR, is upregulated by hypoxia, "The Journal of Biological Chemistry, vol. 272, no. 38, pp. 23659-23667, 1997.
83. J. Waltenberger, U. Mayr, S. Pentz, and V. Hombach, "Functional upregulation of the vascular endothelial growth factor receptor KDR by hypoxia, " Circulation, vol. 94, no. 7, pp. 1647-1654, 1996.
84. C. W. Pugh and P. J. Ratcliffe, "Regulation of angiogenesis by hypoxia: role of the HIF system, " Nature Medicine, vol. 9, no. 6, pp. 677-684, 2003.
85. D. R. Mole, C. Blancher, R. R. Copley et al., "Genome-wide association of hypoxia-inducible factor (HIF)-1 and HIF-2 DNA binding with expression profiling of hypoxia-inducible transcripts, "The Journal of Biological Chemistry, vol. 284, no. 25, pp. 16767-16775, 2009.
86. J. Schodel, S. Oikonomopoulos, J. Ragoussis, C. W. Pugh, P. J. Ratcliffe, and D. R. Mole, "High-resolution genome-wide mapping of HIF-binding sites by ChIP-seq, " Blood, vol. 117, no. 23, pp. e207-e217, 2011.
87. P. Carmeliet and R. K. Jain, "Molecular mechanisms and clinical applications of angiogenesis, " Nature, vol. 473, no. 7347, pp. 298-307, 2011.
88. Y. Ben-Yosef, A. Miller, S. Shapiro, and N. Lahat, "Hypoxia of endothelial cells leads to MMP-2-dependent survival and death, " The American Journal of Physiology-Cell Physiology, vol. 289, no. 5, pp. C1321-C1331, 2005.
89. S. Keely, L. E. Glover, C. F. MacManus et al., "Selective induction of integrin 1 by hypoxia-inducible factor: implications for wound healing, " The FASEB Journal, vol. 23, no. 5, pp. 1338-1346, 2009.
90. N. Skuli, L. Liu, A. Runge et al., "Endothelial deletion of hypoxia-inducible factor-2 (HIF-2) alters vascular function and tumor angiogenesis, " Blood, vol. 114, no. 2, pp. 469-477, 2009.
91. H. Niemi, K. Honkonen, P. Korpisalo et al., "HIF-1 and HIF-2induce angiogenesis and improve muscle energy recovery, " European Journal of Clinical Investigation, vol. 44, no. 10, pp. 989-999, 2014.
92. C. Yuan, P. Wang, L. Zhu et al., "Coculture of stem cells from apical papilla and human umbilical vein endothelial cell under hypoxia increases the formation of three-dimensional vessellike structures in vitro, " Tissue Engineering Part A, vol. 21, no. 5-6, 2015.
93. S. Rajagopalan, J. Olin, S. Deitcher et al., "Use of a constitutively active hypoxia-inducible factor-1 transgene as a therapeutic strategy in no-option critical limb ischemia patients: phase I dose-escalation experience, " Circulation, vol. 115, no. 10, pp. 1234-1243, 2007.
94. L. Holmgren, M. S. OReilly, and J. Folkman, "Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression, " Nature Medicine, vol. 1, no. 2, pp. 149-153, 1995.
95. J. Folkman, "Tumour angiogenesis, " in Cancer Medicine, J. F. Holl and , R. C. Bast Jr., D. L. Morton, E. Frei III, D. W. Kufe, and R. R. Weichselbaum, Eds., pp. 181-204, Williams&Wilkins, Baltimore, Md, USA, 1997.
96. E. B. Rankin and A. J. Giaccia, "The role of hypoxia-inducible factors in tumorigenesis, " Cell Death and Differentiation, vol. 15, no. 4, pp. 678-685, 2008.
97. J. M. Brown and A. J. Giaccia, "The unique physiology of solid tumours: opportunities ( and problems) for cancer therapy, " Cancer Research, vol. 58, no. 7, pp. 1408-1416, 1998.
98. G. L. Semenza, "Hypoxia, clonal selection, and the role of HIF-1 in tumor progression, " Critical Reviews in Biochemistry and Molecular Biology, vol. 35, no. 2, pp. 71-103, 2000.
99. R. Ravi, B. Mookerjee, Z. M. Bhujwalla et al., "Regulation of tumor angiogenesis by p53-induced degradation of hypoxiainducible factor 1, " Genes and Development, vol. 14, no. 1, pp. 34-44, 2000.
100. W. Zundel, C. Schindler, D. Haas-Kogan et al., "Loss of PTEN facilitatesHIF-1-mediated gene expression, " Genes and Development, vol. 14, no. 4, pp. 391-396, 2000.
101. E. Laughner, P. Taghavi, K. Chiles, P. C. Mahon, and G. L. Semenza, "HER2 (neu) signaling increases the rate of hypoxiainducible factor 1 (HIF-1) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression, " Molecular and Cellular Biology, vol. 21, no. 12, pp. 3995-4004, 2001.
102. W. G. Kaelin Jr., "Molecular basis of the VHL hereditary cancer syndrome, " Nature Reviews Cancer, vol. 2, no. 9, pp. 673-682, 2002.
103. P. H. Maxwell, M. S. Wlesener, G.W. Chang et al., "The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis, " Nature, vol. 399, no. 6733, pp. 271-275, 1999.
104. O. Iliopoulos, A. Kibel, S. Gray, and W. G. Kaelin Jr., "Tumour suppression by the human von Hippel-Lindau gene product, " Nature Medicine, vol. 1, no. 8, pp. 822-826, 1995.
105. K. Kondo, J. Klco, E. Nakamura, M. Lechpammer, and W. G. Kaelin Jr., "Inhibition ofHIF is necessary for tumor suppression by the von Hippel-Lindau protein, " Cancer Cell, vol. 1, no. 3, pp. 237-246, 2002.
106. J. K. Maranchie, J. R. Vasselli, J. Riss, J. S. Bonifacino, W. M. Linehan, and R. D. Klausner, "The contribution of VHL substrate binding and HIF1-to the phenotype of VHL loss in renal cell carcinoma, " Cancer Cell, vol. 1, no. 3, pp. 247-255, 2002.
107. R. R. Raval, K. W. Lau, M. G. B. Tran et al., "Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma, " Molecular and Cellular Biology, vol. 25, no. 13, pp. 5675-5686, 2005.
108. H. Lu, R. A. Forbes, and A. Verma, "Hypoxia-inducible factor 1 activation by aerobic glycolysis implicates the Warburg effect in carcinogenesis, "The Journal of Biological Chemistry, vol. 277, no. 26, pp. 23111-23115, 2002.
109. Z. Wang, C. Dabrosin, X. Yin et al., "Broad targeting of angiogenesis for cancer prevention and therapy, " Seminars in Cancer Biology, 2015.
110. P. N. Span and J. Bussink, "Biology of hypoxia, " Seminars in Nuclear Medicine, vol. 45, no. 2, pp. 101-109, 2015.
111. A. Zimna, A. Janeczek, N. Rozwadowska et al., "Biological properties of human skeletal myoblasts genetically modified to simultaneously overexpress the pro-angiogenic factors vascular endothelial growth factor-A and fibroblast growth factor-4, " Journal of Physiology and Pharmacology, vol. 65, no. 2, pp. 193-207, 2014.
112. S. Kolakowski Jr., M. F. Berry, P. Atluri et al., "Placental growth factor provides a novel local angiogenic therapy for ischemic cardiomyopathy, " Journal of Cardiac Surgery, vol. 21, no. 6, pp. 559-564, 2006.
113. S. Rajagopalan, E. R. Mohler III, R. J. Lederman et al., "Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: a phase II r and omized, double-blind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication, " Circulation, vol. 108, no. 16, pp. 1933-1938, 2003.
114. R. J. Lederman, F. O. Mendelsohn, R. D. and erson et al., "TRAFFICInvestigators. Therapeutic angiogenesiswith recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a r and omised trial, " The Lancet, vol. 359, no. 9323, pp. 2953-2958, 2002.
115. K. Hirota and G. L. Semenza, "Regulation of angiogenesis by hypoxia-inducible factor 1, " Critical Reviews in Oncology/ Hematology, vol. 59, no. 1, pp. 15-26, 2006.
116. T. H. Patel, H. Kimura, C. R. Weiss, G. L. Semenza, and L. V. Hofmann, "Constitutively active HIF-1 improves perfusion and arterial remodeling in an endovascular model of limb ischemia, " Cardiovascular Research, vol. 68, no. 1, pp. 144-154, 2005.
117. B. D. Kelly, S. F. Hackett, K. Hirota et al., "Cell type-specific regulation of angiogenic growth factor gene expression and induction of angiogenesis in nonischemic tissue by a constitutively active form of hypoxia-inducible factor 1, " Circulation Research, vol. 93, no. 11, pp. 1074-1081, 2003.
118. C. Yang, H. Liu, and D. Liu, "Mutant hypoxia-inducible factor 1 modified bone marrow mesenchymal stem cells ameliorate cerebral ischemia, " International Journal ofMolecularMedicine, vol. 34, no. 6, pp. 1622-1628, 2014.
119. K.-G. Shyu, M.-T. Wang, B.-W. Wang et al., "Intramyocardial injection of naked DNA encoding HIF-1/VP16 hybrid to enhance angiogenesis in an acute myocardial infarction model in the rat, " Cardiovascular Research, vol. 54, no. 3, pp. 576-583, 2002.
120. D. A. Elson, G. Thurston, L. E. Huang et al., "Induction of hypervascularity without leakage or inflammation in transgenic mice overexpressing hypoxia-inducible factor-1, " Genes and Development, vol. 15, no. 19, pp. 2520-2532, 2001.
121. M. Milkiewicz, C. W. Pugh, and S. Egginton, "Inhibition of endogenous HIF inactivation induces angiogenesis in ischaemic skeletal muscles of mice, " Journal of Physiology, vol. 560, no. 1, pp. 21-26, 2004.
122. G. L. Wang and G. L. Semenza, "Desferrioxamine induces erythropoietin gene expression and hypoxia-inducible factor 1 DNA-binding activity: Implications for models of hypoxia signal transduction, " Blood, vol. 82, no. 12, pp. 3610-3615, 1993.
123. X. Liu, J. Wang, X. Ji, S. Yu, and L. Wei, "Preconditioning of bone marrow mesenchymal stem cells by prolyl hydroxylase inhibition enhances cell survival and angiogenesis in vitro and after transplantation into the ischemic heart of rats, " Stem Cell Research &Therapy, vol. 5, no. 5, p. 111, 2014.
124. J. Li, M. Post, R. Volk et al., "PR39, a peptide regulator of angiogenesis, " Nature Medicine, vol. 61, pp. 49-55, 2000.
125. K. Mittal, H. Koon, P. Elson et al., "Dual VEGF/VEGFR inhibition in advanced solid malignancies, " Cancer Biology & Therapy, vol. 15, no. 8, pp. 975-981, 2014.
126. Y. Hu, J. Liu, and H. Huang, "Recent agents targetingHIF-1 for cancer therapy, " Journal of Cellular Biochemistry, vol. 114, no. 3, pp. 498-509, 2013.
127. D. H. Shin, Y.-S. Chun, D. S. Lee, L. E. Huang, and J.-W. Park, "Bortezomib inhibits tumor adaptation to hypoxia by stimulating the FIH-mediated repression of hypoxia-inducible factor-1, " Blood, vol. 111, no. 6, pp. 3131-3136, 2008.
128. E. J. Yeo, Y. S. Chun, Y. S. Cho et al., "YC-1: a potential anticancer drug targeting hypoxia-inducible factor 1, " Journal of the National Cancer Institute, vol. 95, no. 7, pp. 516-525, 2003.
129. P. Garcia-Maceira and J. Mateo, "Silibinin inhibits hypoxiainducible factor-1 and mTOR/p70S6K/4E-BP1 signalling pathway in human cervical and hepatoma cancer cells: implications for anticancer therapy, " Oncogene, vol. 28, no. 3, pp. 313-324, 2009.
130. Y. M. Lee, S.-H. Kim, H.-S. Kim et al., "Inhibition of hypoxiainduced angiogenesis by FK228, a specific histone deacetylase inhibitor, via suppression of HIF-1 activity, " Biochemical and Biophysical Research Communications, vol. 300, no. 1, pp. 241-246, 2003.
131. S. Shankar, R. Davis, K. P. Singh, R. Kurzrock, D. D. Ross, and R. K. Srivastava, "Suberoylanilide hydroxamic acid (Zolinza/vorinostat) sensitizes TRAIL-resistant breast cancer cells orthotopically implanted in BALB/c nude mice, "Molecular CancerTherapeutics, vol. 8, no. 6, pp. 1596-1605, 2009.
132. E. W. Newcomb, M. A. Ali, T. Schnee et al., "Flavopiridol downregulates hypoxia-mediated hypoxia-inducible factor-1 expression in human glioma cells by a proteasome-independent pathway: implications for in vivo therapy, " Neuro-Oncology, vol. 7, no. 3, pp. 225-235, 2005.
133. M. V. Blagosklonny, "Flavopiridol, an inhibitor of transcription: implications, problems and solutions, " Cell Cycle, vol. 3, no. 12, pp. 1537-1542, 2004.
134. C. J. Yeom, L. Zeng, Y. Zhu, M. Hiraoka, and H. Harada, "Strategies to assess hypoxic/HIF-1-active cancer cells for the development of innovative radiation therapy, " Cancers, vol. 3, no. 3, pp. 3610-3631, 2011.